In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate

被引:62
作者
Taguchi, T
Sugiura, M
Hamada, Y
Miwa, I [1 ]
机构
[1] Meijo Univ, Fac Pharm, Dept Pathobiochem, Tempaku Ku, Nagoya, Aichi 468, Japan
[2] Meijo Univ, Fac Pharm, Dept Organ Mfg, Nagoya, Aichi 468, Japan
关键词
aminoguanidine; pyridoxal; pyridoxal 5 '-phosphate; pyridoxine; diabetes; glycation;
D O I
10.1016/S0006-2952(98)00010-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aminoguanidine (AG) is considered to be a promising compound for the treatment of diabetic complications. We examined the in vitro and in vivo formation of Schiff bases of AG with pyridoxal 5'-phosphate (PLP) and pyridoxal (PL). AG reacted in vitro far more rapidly with PLP to form a Schiff base (PLP-AG) than with PL to form another Schiff base (PL-AG). Administration of AG at 7 mM in drinking water for 18 weeks caused the formation of PLP-AG in the liver and kidney of mice (12.1 +/- 1.6 and 3.8 +/- 0.64 nmol/g of tissue, respectively, mean +/- SD, N = 6). The amount of PLP in the liver of mice AG administered was significantly lower than that of control mice (4.0 +/- 1.4 vs 17.4 +/- 1.3 nmol/g of wet tissue, mean +/- SD, N = 6). Simultaneous administration of pyridoxine (1 mM in drinking water) with AG (7 mM in drinking water) did not ameliorate the decrease in tissue PLP and caused the excess formation of PLP-AG. The results suggest that attention should he paid to the deficiency of tissue PLP in the clinical use of AG. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:1667 / 1671
页数:5
相关论文
共 18 条
[1]   Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: Comparison with aminoguanidine [J].
Booth, AA ;
Khalifah, RG ;
Hudson, BG .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 220 (01) :113-119
[2]   ADVANCED GLYCOSYLATION ENDPRODUCTS IN DIABETIC RENAL-DISEASE - CLINICAL MEASUREMENT, PATHOPHYSIOLOGICAL SIGNIFICANCE, AND PROSPECTS FOR PHARMACOLOGICAL INHIBITION [J].
BUCALA, R ;
VLASSARA, H .
BLOOD PURIFICATION, 1995, 13 (3-4) :160-170
[3]   EFFECTS OF AMINOGUANIDINE ON PERIPHERAL-NERVE FUNCTION AND POLYOL PATHWAY METABOLITES IN STREPTOZOTOCIN-DIABETIC RATS [J].
CAMERON, NE ;
COTTER, MA ;
DINES, K ;
LOVE, A .
DIABETOLOGIA, 1992, 35 (10) :946-950
[4]   SERUM PYRIDOXAL AND FOLATE CONCENTRATIONS IN DIABETICS [J].
DAVIS, RE ;
CALDER, JS ;
CURNOW, DH .
PATHOLOGY, 1976, 8 (02) :151-156
[5]   MECHANISTIC STUDIES OF ADVANCED GLYCOSYLATION END-PRODUCT INHIBITION BY AMINOGUANIDINE [J].
EDELSTEIN, D ;
BROWNLEE, M .
DIABETES, 1992, 41 (01) :26-29
[6]   A DEFICIENCY OF VITAMIN-B6 IS A PLAUSIBLE MOLECULAR-BASIS OF THE RETINOPATHY OF PATIENTS WITH DIABETES-MELLITUS [J].
ELLIS, JM ;
FOLKERS, K ;
MINADEO, M ;
VANBUSKIRK, R ;
XIA, LJ ;
TAMAGAWA, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 179 (01) :615-619
[7]  
HAMMES HP, 1994, DIABETOLOGIA, V37, P32
[8]   INHIBITORY EFFECTS OF PYRIDOXAL-PHOSPHATE, ASCORBATE AND AMINOGUANIDINE ON NONENZYMATIC GLYCOSYLATION [J].
KHATAMI, M ;
SULDAN, Z ;
DAVID, I ;
LI, W ;
ROCKEY, JH .
LIFE SCIENCES, 1988, 43 (21) :1725-1731
[9]   ROLE OF PYRIDOXAL-PHOSPHATE PYRIDOXINE IN DIABETES - INHIBITION OF NONENZYMATIC GLYCOSYLATION [J].
KHATAMI, M .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 585 :502-504
[10]   AMINOGUANIDINE EFFECTS ON NERVE BLOOD-FLOW, VASCULAR-PERMEABILITY, ELECTROPHYSIOLOGY, AND OXYGEN FREE-RADICALS [J].
KIHARA, M ;
SCHMELZER, JD ;
PODUSLO, JF ;
CURRAN, GL ;
NICKANDER, KK ;
LOW, PA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (14) :6107-6111